Chemistry:Flotetuzumab

Short description: Monoclonal antibody

Flotetuzumab
Monoclonal antibody
Type	Di-single-chain variable fragment
Source	Humanized (from mouse)
Target	CD3, CD123
Clinical data
Other names	MGD006
ATC code	none
Identifiers
CAS Number	1664355-28-5
ChemSpider	none
UNII	0AHT0IC02G
KEGG	D11306
Chemical and physical data
Formula	C₂₆₁₈H₄₀₄₀N₇₀₄O₈₁₃S₁₆
Molar mass	58898.19 g·mol⁻¹

Flotetuzumab (INN;^[1] development code MGD006) is a bispecific antibody^[2] designed for the treatment of acute myeloid leukemia.^[3]^[4]

This drug is being developed by MacroGenics, Inc.^[5]

References

↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118". WHO Drug Information 31 (4). https://www.who.int/medicines/publications/druginformation/innlists/PL118.pdf.
↑ "Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia". Curr Hematol Malig Rep 13 (6): 417–425. October 2018. doi:10.1007/s11899-018-0472-8. PMID 30280288.
↑ "Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity". Clin. Cancer Res. 24 (11): 2631–2641. June 2018. doi:10.1158/1078-0432.CCR-17-2265. PMID 29463552. .
↑ "Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors". Curr. Opin. Hematol. 25 (2): 136–145. March 2018. doi:10.1097/MOH.0000000000000401. PMID 29206680.
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab, American Medical Association.

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab^§ Ascrinvacumab^§ Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin^† Enoticumab^§ Figitumumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Tarextumab^§ Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^† "-melu-" (melanoma) Flanvotumab^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox^† Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab^† Loncastuximab tesirine Margetuximab^† Rituximab^# Siltuximab Ublituximab^† IMAB362 "-mexi-" (melanoma): Ecromeximab^§
Humanized ("-tuzu-")	Abituzumab^§ Alemtuzumab Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab^§ Emibetuzumab^§ Enoblituzumab^§ Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin^‡ Imgatuzumab^§ Inotuzumab ozogamicin^† Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin^† Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan^† Sibrotuzumab^§ Simtuzumab^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Flotetuzumab. Read more

Anonymous

Search

Chemistry:Flotetuzumab

Namespaces

More

Page actions

References

Navigation

Navigation

Help

googletranslator

Navigation

Wiki tools

Wiki tools

Anonymous

Search

Chemistry:Flotetuzumab

References

Navigation

Wiki tools

Page tools

Other projects

Categories